Liraglutide Price Comparison — Compare 1 Vendors
Save ~91% vs Manufacturer direct
Research-grade Liraglutide is for laboratory and research use only, not approved for human consumption. Always consult a licensed physician before working with any compound. FDA-approved 2014 (Victoza) and 2014 (Saxenda). No direct-to-consumer cash-pay program. Daily injection (vs weekly for newer GLP-1s) reduces popularity; retail price has stayed high.
See all Liraglutide vendors →Price Comparison
Compare vendors
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| CertaPeptides7.5/10Out of stock | $120.97 | $4.03 | Jun 27, 2026 | Buy → |
Research details
Liraglutide — research data
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Overview
About Liraglutide
Mechanism of action
GLP-1 receptor agonist (97% homology to human GLP-1); stimulates insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite. Daily injection (vs. weekly for semaglutide).
Safety profile
Nausea, vomiting, diarrhea, constipation; pancreatitis risk; thyroid C-cell tumor risk (rodents); gallbladder disease; injection site reactions. · Extensive data; GI side effects; thyroid warning (animal); cardiovascular benefit demonstrated
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Liraglutide below your target.
Related pages
More on Liraglutide
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- The SCALE Obesity trial (NEJM 2015, n=3,731) demonstrated that liraglutide 3.0 mg as Saxenda produced a mean 8.4% body weight reduction vs 2.8% with placebo over 56 weeks — with 63.2% of participants achieving ≥5% weight loss, leading to FDA approval for chronic weight management.
- The LEADER cardiovascular outcomes trial (NEJM 2016, n=9,340) showed liraglutide 1.8 mg significantly reduced the MACE composite endpoint by 13% (HR 0.87, p=0.01) in T2D patients at high cardiovascular risk over a median 3.8 years — establishing the first cardiovascular mortality benefit for a GLP-1 agonist.